1. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. (February 2021) Authors: Bruce, Ian N; Nami, Alireza; Schwetje, Erik; Pierson, M Edward; Rouse, Tomas; Chia, Yen Lin; Kuruvilla, Denison; Abreu, Gabriel; Tummala, Raj; Lindholm, Catharina Journal: Lancet Issue: Volume 3:Number 2(2021) Page Start: e101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗